Routine diagnostic BRCA1 and BRCA2 gene screening for deleterious mutations is typically performed for individuals from suspected high-risk breast-ovarian canc... read more
The effects of resveratrol’s derivatives on VEGF, IL-6, IL-8 and NF-kB in ovarian cancer in vitro and in vivo studiesSupport this project
Women with advanced ovarian cancer normally have a poor outcome because the tumour has spread within the abdominal cavity at the time of diagnosis. Most women with advanced disease show the sign of building up ofbody fluid; this becomes a clinical challenge for the current treatment management.
Treatments currently available can prolong time of survival, but tumours become resistant to treatment and a cure is rare. In order to prolong time of patient survival, a new form of anti-cancer drugs, showing less side effects and being low cost, is urgently needed. Resveratrol is a food compound and has been found to show anti-tumour activity in a laboratory. But its anti tumour activities are uncertain in humans because resveratrol is highly metabolized and rapidly secreted from the body.
Therefore, compounds that are structurally related to resveratrol may be useful to investigate their anti-tumour activities in human. We are very interested in derivatives of resveratrol and we want to investigate if these derivatives can exhibit anti-cancer activities in a laboratory before we could use them in humans.
Dr Chitcholtan research interests are focusing on the activity of tyrosine kinases, targeted inhibitors, effects of ascitic fluid, and anti-tumour properties of natural food compounds in the progression of advanced ovarian cancer.More About Dr Kenny Chitcholtan